CELLINK Inaugurates Good Manufacturing Practice (GMP) Lab at Their Kallebäck Location to Enable Clinical Grade Bioinks for Human Applications.

As part of BICO’s mission to reduce the impact due to organ shortages, CELLINK a part of BICO Bioprinting will now be able to provide bioinks produced in the newly opened Good Manufacturing Practice (GMP) bioink facility to support an increasing demand for Tissue Engineered Medical Products (TEMPs) in clinics. 

CELLINK, a BICO Company and the global leader in providing 3D bioprinters and biomaterials, announced today the opening of their Good Manufacturing Practice (GMP) facility to provide world class bioinks for pharmaceutical, medical researchers and manufacturers that want to comply with FDA and EU quality and safety regulations, an essential step for clinical applications. This marks an important milestone on the journey to reducing the impact of organ shortages. Tissue Engineering Medical Products represent a USD 2 Billion industry and thanks to the advancements in 3D bioprinting, the field is rapidly advancing. Given regulations any material used in the development of TEMPs must adhere to the GMP requirements. With the opening of this lab, CELLINK will be able to better serve their customers as the premier provider of biomaterials and serve as a partner to them as they continue to push the boundaries of tissue engineering and regenerative medicine.

“It gives me great pride to officially open our new lab. For the last 5 years we have worked on tailoring materials for a diverse range of applications, with the highest emphasis on quality. With the opening of this lab, we can continue this journey and provide our customers with the materials they need along with the appropriate certifications to support their progress” says Itedale Namro Redwan, CSO, CELLINK.

“With a GMP facility in the Gothenburg area, CELLINK continues to lead the way in developing the life science industry in the region. We look forward to working with our customers and colleagues across the globe to drive forward the world of 3D bioprinting” adds Cecilia Edebo, CEO, CELLINK.

CELLINK will host an open house with a tour of the facility on May 3rd 2022 at 16:30 PM CET. We welcome you to register for the event by following this link here.

More News